Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
BioCardia Inc (BCDA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$0.89-2.53%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for BCDA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage operating losses and negative cash flow | A primary condition in BioCardia Inc's published investment case. The stated target is reduce operating losses and cash burn compared to -$2.73M. | Broken | operating losses worsen beyond -$2.73M and cash burn increases | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk speculative development-stage business, not a proven durable compounder. The long-term thesis is on watch: management has described clinical and regulatory work, but the supplied evidence does not establish strong delivery or a clear revenue base.
The valuation model indicates a durable premium versus peers, but its confidence is low. The evidence does not show which specific expectations explain that premium, and the muted price reaction does not establish that the risks are fully reflected.
Near term, earnings-miss risk is elevated, with a recent miss, erratic surprises, and operating losses; revenue was not reported in the supplied financials. Management has described CardiAMP enrollment and Japan submission preparation, while FDA acceptance of a revised Helix pre-submission is a concrete step; enrollment totals and a signed commercial partnership are not evidenced.
Over the next few quarters, the thesis depends on whether management meets its stated clinical and regulatory milestones without cutting guidance. A weakening jobs trend could weigh on healthcare businesses, while continued strength from sector bellwethers could support the sector backdrop; recent litigation and a listing-rule notice add risks.
For a 1 to 3 year view, BCDA remains a high-risk watch case with early regulatory progress but limited proof of clinical delivery, commercial traction, or financial strength. The thesis hinges on execution and the resolution of near-term business risks. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Management plans to fix Nasdaq listing issues. |
| Intact |
| equity remains below $2.5 million by 2026-Q2 |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve initial PMDA approval for treatment subgroup of 20,000 patients | BioCardia aims to get initial PMDA approval for 20,000 patients. | Improving | approval not granted by 2026-Q2 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.53 → $-0.52 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.53 | $50,000 | 1 / 2 |
| 2026-07-25 | $-0.53 | $50,000 | 1 / 2 |
| 2026-07-26 | $-0.53 | $50,000 | 1 / 2 |
| 2026-07-27 | $-0.53 | $50,000 | 1 / 2 |
| 2026-07-28 | $-0.60 | $0 | 1 / 2 |
| 2026-07-29 | $-0.60 | $0 | 1 / 2 |
| 2026-07-30 | $-0.60 | $0 | 1 / 2 |
| 2026-07-31 | $-0.60 | $0 | 1 / 2 |
| 2026-08-01 | $-0.53 | $50,000 | 1 / 2 |
| 2026-08-02 | $-0.60 | $0 | 1 / 2 |
| 2026-08-03 | $-0.60 | $0 | 1 / 2 |
| 2026-08-04 | $-0.60 | $0 | 1 / 2 |
| 2026-08-05 | $-0.60 | $0 | 1 / 2 |
| 2026-08-06 | $-0.60 | $0 | 1 / 2 |
| 2026-08-07 | $-0.53 | $50,000 | 1 / 2 |
| 2026-08-08 | $-0.60 | $0 | 1 / 2 |
| 2026-08-09 | $-0.60 | $0 | 1 / 2 |
| 2026-08-10 | $-0.60 | $0 | 1 / 2 |
| 2026-08-11 | $-0.60 | $0 | 1 / 2 |
| 2026-08-12 | $-0.60 | $0 | 1 / 2 |
| 2026-08-13 | $-0.60 | $0 | 1 / 2 |
| 2026-08-14 | $-0.53 | $50,000 | 1 / 2 |
| 2026-08-15 | $-0.53 | $50,000 | 1 / 2 |
| 2026-08-16 | $-0.53 | $50,000 | 1 / 2 |
| 2026-08-17 | $-0.53 | $50,000 | 1 / 2 |
| 2026-08-18 | $-0.53 | $50,000 | 1 / 2 |
| 2026-08-19 | $-0.53 | $50,000 | 1 / 2 |
| 2026-08-20 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-21 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-22 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-23 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-24 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-25 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-26 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-27 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-28 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-29 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-30 | $-0.52 | $50,000 | 1 / 2 |
| 2026-08-31 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-01 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-02 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-03 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-04 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-05 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-06 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-07 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-08 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-09 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-10 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-11 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-12 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-13 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-14 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-15 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-16 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-17 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-18 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-19 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-20 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-21 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-22 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-23 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-24 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-25 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-26 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-27 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-28 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-29 | $-0.52 | $50,000 | 1 / 2 |
| 2026-09-30 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-01 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-02 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-03 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-04 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-05 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-06 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-07 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-08 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-09 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-10 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-11 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-12 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-13 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-14 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-15 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-16 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-17 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-18 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-19 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-20 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-21 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-22 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-23 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-24 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-25 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-26 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-27 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-28 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-29 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-30 | $-0.52 | $50,000 | 1 / 2 |
| 2026-10-31 | $-0.52 | $50,000 | 1 / 2 |
| 2026-11-01 | $-0.52 | $50,000 | 1 / 2 |
| 2026-11-02 | $-0.52 | $50,000 | 1 / 2 |
| 2026-11-03 | $-0.52 | $50,000 | 1 / 2 |
| 2026-11-04 | $-0.52 | $50,000 | 1 / 2 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 2 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.